EXPORUM
Global coffee figures and baristas will gather at BEXCO, Busan in May.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424527060/en/
World of Coffee & World Barista Championship Busan is held from May 1st to 4th at BEXCO, Busan. (Graphic: EXPORUM)
Specialty coffee industry professionals from around the world will gather at BEXCO, Busan, from May 1-4, 2024, for the inaugural World of Coffee in Asia. This event will also feature the 2024 World Barista Championship, bringing together top baristas from across the globe. The Specialty Coffee Association (SCA) is working with host Busan Metropolitan City and organizer EXPORUM, with support of the 2024 Portrait Country, Indonesia, to debut World of Coffee in Busan, marking a significant milestone for the Asian coffee community. Over 20,000 global attendees, including 12,000 industry professionals from 70+ countries, are expected to visit BEXCO, anticipating contributions not only to the event but also to local economic activation.
At the 'World of Coffee 2024,' more than 280 domestic and international coffee companies will participate, showcasing coffee-related products, technologies, and services, including the Roaster Village exhibition to introduce domestic and international roastery cafes and brands. Additionally, activities such as networking with global coffee enthusiasts at the 'SCA Community Lounge,' experiencing and evaluating various domestic and international coffees in the 'Cupping Room,' and engaging in seminars to experience and promote new coffee cultures will be conducted, creating a platform for diverse experiences and trends representing the global coffee event.
The World Barista Championship will return to Korea after seven years where it was last held at Cafe Show Seoul. Competitors demonstrate their expertise in crafting innovative espresso-based drinks across the espresso, milk, and signature beverage courses, with the cutting-edge approaches and tools used on stage having extensive and enduring impacts on the industry.
Yannis Apostolopoulos, President of the Specialty Coffee Association, hosting 'World of Coffee & World Barista Championship Busan 2024,' expressed expectations that this event will serve as a significant starting point for Korea's coffee industry development and a new chapter for 'World of Coffee Asia' to shape the cultural and future landscape of the Asian coffee market.
Early bird tickets are available on the World of Coffee Asia official website until April 28th and then will only be available for purchase at the show. For exhibiting and ticket registration please visit: https://asia.worldofcoffee.org/
[Reference] ‘World of Coffee & World Barista Championship Busan 2024’ Overview
- Title: World of Coffee & World Barista Championship Busan 2024
- Schedule: 1 (Wed) ~ 4 (Sat) May 2024, 4 days, 10:00~17:00
- Location: Exhibition Center 1, BEXCO, Busan, Republic of Korea
- Owned by: Specialty Coffee Association (SCA)
- Hosted by: Busan Metropolitan City
- Organized by: Busan Technopark, EXPORUM
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424527060/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera1.6.2025 14:00:00 CEST | Press release
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpointAll key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomesNo serious adverse events considered related to rusfertide were reportedRusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary e
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom